Blog
RSS FeedPosted by Michael Wonder on 25 Nov 2021
Preparing for health care’s new frontier: Committee releases major report on reforming the process for new medicines and health technology
25 November 2021 - A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant ...
Posted by Michael Wonder on 25 Nov 2021
MTAA welcomes new frontiers report
25 November 2021 - The Medical Technology Association of Australia wishes to thank Trent Zimmerman MP and Dr Mike Freelander MP ...
Posted by Michael Wonder on 24 Nov 2021
Semaglutide (Wegovy) stakeholder meeting outcome statement
24 November 2021 - The outcome statement for the semaglutide stakeholder meeting held on 26 August 2021 is now available. ...
Posted by Michael Wonder on 17 Nov 2021
ICER publishes final evidence report and policy recommendations on mavacamten for hypertrophic cardiomyopathy
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
Posted by Michael Wonder on 13 Nov 2021
Public Summary Documents (first time rejections and deferrals) – July 2021 PBAC meeting
12 November 2021 - The Public Summary Documents (first time rejections and deferrals) from the July 2021 PBAC meeting are now ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 05 Nov 2021
Drug Utilisation Sub-Committee outcome statement
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 17 Sep 2021
ICER releases draft evidence report on therapies for severe asthma
16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Sep 2021
ICER publishes evidence report on treatments for myasthenia gravis
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
Posted by Michael Wonder on 10 Sep 2021
PBAC Public Summary Documents (first time decisions not to recommend, deferrals and other matters) – May 2021 meeting
10 September 2021 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the May ...
Posted by Michael Wonder on 30 Aug 2021
Public Summary Documents – May 2021 PBAC meeting
27 August 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2021 PBAC ...
Posted by Michael Wonder on 19 Aug 2021
TGA reduces timeframe for publishing adverse event reports
19 August 2021 - With strong public interest in adverse event reports relating to COVID-19 vaccinations, and improvements in our ...
Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...